Trials / Recruiting
RecruitingNCT03684018
Two Dose Levels of Privigen in Pediatric CIDP
Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IgPro10 | Normal human immunoglobulin G administered intravenously |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2029-12-20
- Completion
- 2029-12-20
- First posted
- 2018-09-25
- Last updated
- 2025-10-20
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03684018. Inclusion in this directory is not an endorsement.